STOCK TITAN

Jaguar Health Inc - JAGX STOCK NEWS

Welcome to our dedicated news page for Jaguar Health (Ticker: JAGX), a resource for investors and traders seeking the latest updates and insights on Jaguar Health.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Jaguar Health's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Jaguar Health's position in the market.

Rhea-AI Summary
Napo Pharmaceuticals provides fiscal support for a quality of life survey for individuals with a diagnosis or history of cancer, receiving over 500 responses. The findings may inform research, clinical care, and the cancer community on addressing quality-of-life impacts through improvements in supportive care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.22%
Tags
none
-
Rhea-AI Summary
Magdalena Biosciences successfully completes import of coca leaf for research on mental health indications. Import authorized by Peruvian Health Authority. Potential benefits for ADHD, depression, and anxiety. ADHD market projected to reach $18.69 billion by 2030. Unmet needs in current treatments for anxiety and depression. Partnership with Filament Health and Psilo Scientific facilitated import.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.07%
Tags
none
-
Rhea-AI Summary
Jaguar Health expects top line results for its phase 3 OnTarget trial of crofelemer in late October 2023. They are also supporting studies for crofelemer in rare disease indications, with results expected by the end of 2023 and in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.22%
Tags
none
Rhea-AI Summary
Napo Pharmaceuticals, a Jaguar Health family company, has been issued a new patent for methods of treating rare diseases using crofelemer. The patent enhances the company's intellectual property protection for crofelemer for the treatment of short bowel syndrome (SBS). Jaguar is supporting studies of crofelemer for SBS and microvillus inclusion disease (MVID) with results expected by the end of 2023 and in 2024. Published data from these studies could potentially support early patient access to crofelemer for SBS or MVID. Crofelemer has been granted Orphan Drug Designation for both MVID and SBS with intestinal failure. Napo currently holds approximately 146 patents and 50 patents pending.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.08%
Tags
none
-
Rhea-AI Summary
Napo Pharmaceuticals submits grant application for funding to support Phase I study of NP-300 for the treatment of diarrhea from cholera
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.73%
Tags
none
-
Rhea-AI Summary
Jaguar Health expects top line results for its phase 3 OnTarget trial of crofelemer in late October 2023. They are also supporting proof-of-concept studies for crofelemer in rare disease indications, with results expected by the end of 2023 and in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.94%
Tags
Rhea-AI Summary
Jaguar Health supports proof-of-concept studies for crofelemer in rare diseases, Dr. Brunke joins BIO's Rare Disease and Orphan Drugs Committee
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.22%
Tags
none
-
Rhea-AI Summary
Jaguar Health supports Investigator Initiated Trials for Crofelemer to Treat Two Rare Intestinal Diseases
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.07%
Tags
none
-
Rhea-AI Summary
Napo Pharmaceuticals completes Phase 3 trial for crofelemer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.25%
Tags
conferences acquisition
Rhea-AI Summary
Jaguar engages B2i Digital for digital investor engagement and awareness program
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.29%
Tags
none
Jaguar Health Inc

Nasdaq:JAGX

JAGX Rankings

JAGX Stock Data

24.94M
274.29M
1.78%
0.45%
8.5%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
San Francisco

About JAGX

jaguar health, inc. is a commercial stage natural-products pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global basis. our wholly-owned subsidiary, napo pharmaceuticals, inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. our mytesi® (crofelemer) product is approved by the u.s. fda for the symptomatic relief of noninfectious diarrhea in adults with hiv/aids on antiretroviral therapy. canalevia™ is our lead animal prescription drug candidate, intended for treatment of various forms of diarrhea in dogs. equilevia™ is jaguar’s non-prescription product for total gut health in equine athletes. to read our full social media policy, please visit https://jaguar.health/social-media-policy/